The pharmacokinetics of doxazosin in elderly normotensives.

Abstract

The pharmacokinetics of doxazosin were studied in 12 normotensive elderly volunteers aged 62-89 years. There was marked inter-individual variability in all the parameters derived but the disposition of doxazosin was similar in both sexes. These results were compared to those of a group of young normotensive volunteers aged 23-39 years studied previously under comparable conditions. The volume of distribution increased significantly with age although the bioavailability and clearance were not significantly different in the two groups. These results suggest that age is unlikely to influence the disposition of doxazosin to a clinically significant extent.

Tolerability of -Blockade With Doxazosin as a Therapeutic Option for Symptomatic Benign Prostatic Hyperplasia in the Elderly Patient: A Pooled Analysis of Seven Double-Blind, Placebo-Controlled Studies

“…This is a reflection of the observation that its pharmacokinetic characteristics are also similar in older and younger volunteers (29,30).…”

Doxazosin in the treatment of benign prostatic hyperplasia. A review of the safety profile in older patients

“…Any postural effects can usually be avoided by careful dose titration from an initial 1 mg dose of doxazosin. With respect to the half life of doxazosin, this has been found to be similar in older and younger hypertensive patients 24 and volunteers. 12 …”

Doxazosin in the Older Male: Efficacy in Treating Benign Prostatic Hyperplasia

“…The use of doxazosin in older patients is supported by the similarities in the elimination half-life of doxazosin in older and younger volunteers [19]. Furthermore, it has been demonstrated that bioavailability is not influenced by age.…”